GSK plc (GLAXF) stock
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK plc grew revenue 4.1% to £32.67B over fiscal 2025. Operating income rose 97.3% to £7.93B, moving the operating margin from 12.8% to 24.3%. Free cash flow was £6.39B, up 24.0% from a year earlier. At the latest close the market valued the company at £79.87B, 13.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- £79.87B
- P/E ratio
- 13.3
- Price to sales
- 2.45
- Price to book
- 4.88
- Dividend yield
- –
- Free cash flow yield
- 8.00%
Fundamentals
- Revenue
- £32.67B
- Net income
- £5.72B
- EPS, diluted
- 1.39 GBP
- Free cash flow
- £6.39B
Trading
- Previous close
- $24.44
- Open
- $23.70
- Day's range
- $23.70 – $24.74
- Volume
- 807
- Average volume (20 days)
- 2,272
- Beta (5 years)
- 0.27
- RSI (14 days)
- 51.2
- Volatility (1 year)
- 26.0%
- Relative volume
- 1.14×
- WACC
- 6.9%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | GLAXF | S&P 500 | Difference | GLAXF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.8% | +0.6% | −1.5 pts | ||
| 3 months | -3.1% | +3.4% | −6.5 pts | ||
| Year to date | +2.3% | +13.3% | −11.0 pts | ||
| 1 year | +15.9% | +16.6% | −0.7 pts | ||
| 3 years | +55.5% | +86.4% | −30.8 pts | +15.9% | +23.1% |
| 5 years | +24.6% | +81.9% | −57.3 pts | +4.5% | +12.7% |
| 10 years | +51.4% | +318.9% | −267.4 pts | +4.2% | +15.4% |
Eleven years at a glance
Fiscal years 2015 to 2025, GBP
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About GSK
Pharmaceutical Preparations
GSK operates commercial operations and research and development divisions focused on specialty medicines, general medicines, and vaccines. The company develops and markets pharmaceutical treatments across multiple therapeutic areas, including human immunodeficiency virus (HIV), oncology, respiratory ailments, immunology, and inflammation. In addition, its portfolio features preventative vaccines for conditions such as shingles, meningitis, respiratory syncytial virus (RSV), and influenza. Its customer base includes commercial pharmaceutical wholesalers.
Company profile, executives and historyGSK stock: common questions
What is GSK's stock price?
GLAXF closed at $24.74 on Oct 19, 2026, up 1.21% on the day.
What is GSK's market cap?
GSK was worth $106.83B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is GLAXF's P/E ratio?
GLAXF trades at 13.3 times earnings, based on diluted earnings per share of 1.39 GBP over fiscal 2025.
How much revenue does GSK make?
GSK reported revenue of £32.67B for fiscal 2025, up 4.1% from a year earlier.
Does GSK pay a dividend?
No. GSK has not paid a cash dividend over the last twelve months.
How has GLAXF stock performed over the past year?
Including dividends, GLAXF returned +15.9% over the past year, against +16.6% for the S&P 500.
Who are GSK's competitors?
Companies most similar to GSK by business, industry and size include MRK, BMY, PFE, AZN, VTRS.